Clinical Trial Update: Erlotinib and Chemotherapy for Patients With Stage IB-IIIA NSCLC With EGFR Mutations (ECON) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating erlotinib in combination with chemotherapy for stage IB-IIIA non-small cell lung cancer with EGFR mutations has completed enrollment an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Non Small Cell Lung Cancer, Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2015-11-20